兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300573 兴齐眼药

交易中 03-10 11:28:30

{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":69.89,"timestamp":1773113310000,"preClose":69.01,"halted":0,"volume":3884862,"delay":0,"changeRate":0.0128,"floatShares":190000000,"shares":246000000,"eps":2.6223,"marketStatus":"交易中","change":0.88,"latestTime":"03-10 11:28:30","open":69.7,"high":71.16,"low":69.7,"amount":273000000,"amplitude":0.0212,"askPrice":69.91,"askSize":1,"bidPrice":69.89,"bidSize":15,"shortable":0,"etf":0,"ttmEps":2.6223,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1773113400000},"marketStatusCode":2,"adr":0,"adjPreClose":69.01,"symbolType":"stock","openAndCloseTimeList":[[1773106200000,1773113400000],[1773118800000,1773126000000]],"highLimit":75.91,"lowLimit":62.11,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":246429527,"isCdr":false,"pbRate":9.16,"roa":"--","peRate":26.652176,"roe":"32.91%","epsLYR":1.94,"committee":-0.348837,"marketValue":17223000000,"turnoverRate":0.0205,"status":0,"floatMarketCap":13246000000},"requestUrl":"/m/hq/s/300573/tweets","defaultTab":"tweets","newsList":[{"id":"2617650072","title":"兴齐眼药(300573.SZ)获一项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617650072","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617650072?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:45","pubTimestamp":1772783116,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局核准签发的平衡盐溶液(供灌注用)《药品注册证书》。平衡盐溶液(供灌注用)是一种用于眼组织灌注使用的无菌等张溶液。本品适应症为在眼科手术中，作为眼内或眼外的灌注液，最长灌注时间不得超过60分钟。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2614081119","title":"兴齐眼药：公司专注于眼科制药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2614081119","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614081119?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:05","pubTimestamp":1772021123,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好！请问贵公司如何看待中国新生儿快速下降?对未来公司业绩可能带来的影响?兴齐眼药回复：尊敬的投资者您好！公司将持续关注行业及外部宏观环境的变化。公司专注于眼科制药领域，产品覆盖各年龄段人群，未来将持续聚焦主业，不断提升核心竞争力与经营质量，具体经营情况请以公告信息为准，感谢您的关注。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260225/32027104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01477","BK0177","BK1574","BK0239","300573","BK1191"],"gpt_icon":0},{"id":"2611890701","title":"兴齐眼药：公司管理层考核与公司经营业绩相关","url":"https://stock-news.laohu8.com/highlight/detail?id=2611890701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611890701?lang=zh_cn&edition=full","pubTime":"2026-02-13 12:36","pubTimestamp":1770957373,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价低迷，市值严重不匹配公司业绩，该情况是否纳入公司2025年管理层年度考核？兴齐眼药回复：尊敬的投资者您好。公司始终重视市值管理工作，上市以来一直通过聚焦主业、稳健经营、切实履行信息披露义务、加强投资者沟通等方式，积极向市场传递公司投资价值。公司管理层考核与其承担的责任、风险、完成绩效情况以及公司经营业绩相关，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300017622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2610995513","title":"兴齐眼药：公司持有泰州兴普泰生物制药有限公司3.33%的股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2610995513","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610995513?lang=zh_cn&edition=full","pubTime":"2026-02-12 09:06","pubTimestamp":1770858376,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月12日在投资者关系平台上答复投资者关心的问题。投资者提问：今年国产口服司美格鲁肽将会大批量陆续上市，公司参股公司泰州兴普泰生物制药有限公司今年业绩是否会迎来爆发式增长兴齐眼药回复：尊敬的投资者您好。截至目前，公司持有泰州兴普泰生物制药有限公司3.33%的股权。公司对兴普泰的股权投资属于围绕产业链上下游的战略性投资，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200006261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2608135520","title":"兴齐眼药：采取全渠道营销策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2608135520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608135520?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:06","pubTimestamp":1770192368,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有没有针对青少年儿童的寒假专项营销计划兴齐眼药回复：尊敬的投资者您好，针对青少年儿童近视问题，公司采取全渠道营销策略，通过专业化学术推广、普及近视防控科普教育及完善药事服务体系等多项措施，提升产品可及性与患者用药体验。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400024740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2608290258","title":"兴齐眼药最新公告：SQ-129玻璃体缓释注射液用于糖尿病性黄斑水肿Ⅰ/Ⅱ期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608290258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608290258?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:28","pubTimestamp":1770110880,"startTime":"0","endTime":"0","summary":"兴齐眼药公告称，公司研发的SQ-129玻璃体缓释注射液已完成Ⅰ/Ⅱ期临床试验首例受试者入组，正式进入Ⅰ/Ⅱ期临床试验。该药物为化学药品2.2类，适应症为成年患者的糖尿病性黄斑水肿。Ⅰ/Ⅱ期试验旨在探索SQ-129的安全性和初步疗效，以及其药代动力学特征。目前国内外尚无该产品获批上市。Ⅰ/Ⅱ期试验完成首例受试者入组不会对公司近期业绩产生重大影响。公司将积极推进研发项目，并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300029665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2608120855","title":"兴齐眼药：公司今年销售计划围绕核心业务稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2608120855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608120855?lang=zh_cn&edition=full","pubTime":"2026-02-02 15:39","pubTimestamp":1770017949,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司今年的销售计划及预期是多少？可以说吗兴齐眼药回复：尊敬的投资者您好，公司今年销售计划围绕核心业务稳步推进，整体预期保持稳健增长，具体数值属于内部经营规划信息，暂不便对外披露，还请理解，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200016622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2608687885","title":"股市必读：兴齐眼药（300573）1月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608687885?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:18","pubTimestamp":1769966292,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，兴齐眼药报收于70.1元，下跌1.89%，换手率3.92%，成交量7.44万手，成交额5.26亿元。董秘最新回复投资者： 公司2025年的7亿扣非净利润2026年会不会全部分掉董秘： 尊敬的投资者您好，公司利润分配方案是根据法律法规的要求，在符合利润分配原则、保证公司正常经营和长远发展的前提下，经统筹考虑来拟定。当日关注点来自交易信息汇总：1月30日主力资金净流出3949.92万元，显示主力资金明显离场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2607097109","title":"兴齐眼药：公司利润分配方案是根据法律法规的要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607097109?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:27","pubTimestamp":1769761638,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年的7亿扣非净利润2026年会不会全部分掉兴齐眼药回复：尊敬的投资者您好，公司利润分配方案是根据法律法规的要求，在符合利润分配原则、保证公司正常经营和长远发展的前提下，经统筹考虑来拟定。公司会严格依照相关法律法规及《公司章程》来履行。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000027558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2606950799","title":"兴齐眼药：公司按审慎原则，预测的业绩区间幅度更小","url":"https://stock-news.laohu8.com/highlight/detail?id=2606950799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606950799?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:00","pubTimestamp":1769590835,"startTime":"0","endTime":"0","summary":"兴齐眼药回复：尊敬的投资者您好，业绩预告相关规定要求业绩上下限区间不超过50%，鼓励不超过30%，公司按审慎原则，预测的业绩区间幅度更小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2606218253","title":"兴齐眼药：公司根据相关规定及公告格式要求履行业绩预告披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2606218253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606218253?lang=zh_cn&edition=full","pubTime":"2026-01-26 16:42","pubTimestamp":1769416931,"startTime":"0","endTime":"0","summary":"大部业绩预告都同步预告当期营业收入，希望公司也能同步披露营业收入，以给予投资者稳定的预期。公司根据相关规定及公告格式要求履行业绩预告披露义务，全年营收指标请您关注公司年度报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600018448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2605464130","title":"兴齐眼药最新公告：2025年净利同比预增95.82%-121.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605464130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605464130?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:44","pubTimestamp":1769075082,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)发布2025年度业绩预告，预计归属于上市公司股东的净利润为6.62亿元-7.49亿元，比上年同期增长95.82%-121.56%。报告期内，公司坚持自主研发，巩固核心竞争优势，加大市场拓展力度，持续优化产品结构，深化成本费用管控，推动整体盈利能力提升，经营业绩延续良好增长态势。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200029450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2605463560","title":"1月22日兴齐眼药跌5.27%，华夏中证智选1000成长创新策略ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2605463560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605463560?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:39","pubTimestamp":1769067564,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日兴齐眼药跌5.27%，收盘报78.36元，换手率10.85%，成交量20.57万手，成交额16.53亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为华夏基金的华夏中证智选1000成长创新策略ETF。华夏中证智选1000成长创新策略ETF目前规模为0.54亿元，最新净值1.4716，较上一交易日上涨1.28%，近一年上涨68.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200019730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","399630","BK0239","BK0177"],"gpt_icon":0},{"id":"2605025601","title":"兴齐眼药：技术研究费主要包括临床试验费及其他相关费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2605025601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605025601?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:51","pubTimestamp":1768999886,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药01月20日在投资者关系平台上答复投资者关心的问题。公司将开发具有自主知识产权的新产品作为推动公司持续创新发展的核心战略，近年来持续加大研发投入，技术研究费主要包括临床试验费及其他相关费用。公司高管的薪酬水平与其承担的责任、风险和经营业绩挂钩，未来公司也将根据相关要求，持续完善公司治理结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100038895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2604198297","title":"兴齐眼药：将根据国家医保政策并结合市场情况做出合适决策","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604198297?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:24","pubTimestamp":1768897477,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药01月20日在投资者关系平台上答复投资者关心的问题。优先纳入医保，而且现在有独家的优势，价格谈判起来会更加的容易，为了加速提高渗透率的角度去考虑，还是说贵公司会继续先观望，请问公司在争取医保这件事的是怎么看待的兴齐眼药回复：尊敬的投资者您好，公司将根据国家医保政策并结合市场情况做出合适的决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000023166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2604518602","title":"兴齐眼药(300573.SZ)：SQ-24071滴眼液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604518602","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604518602?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:12","pubTimestamp":1768810334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于SQ-24071滴眼液的《药物临床试验批准通知书》。SQ-24071滴眼液为公司研发的化学药品2.2;2.4类改良型新药。临床拟用于延缓儿童及青少年的近视进展。根据改良型新药的有关要求,公司已经完成SQ-24071滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-24071滴眼液具有良好的安全性及临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2604979708","title":"股市必读：兴齐眼药（300573）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604979708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604979708?lang=zh_cn&edition=full","pubTime":"2026-01-19 01:23","pubTimestamp":1768756988,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，兴齐眼药报收于78.28元，上涨1.89%，换手率6.05%，成交量11.46万手，成交额8.99亿元。董秘： 尊敬的投资者您好，公司0.02%、0.04%硫酸阿托品滴眼液已于2026年1月4日获得由国家药品监督管理局签发的药品注册批件。当日关注点来自“交易信息汇总”：1月16日主力资金净流入4326.27万元，散户资金呈明显净流出态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900000505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2601007015","title":"兴齐眼药（300573）披露获得药品注册证书，1月5日股价上涨4.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007015?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:04","pubTimestamp":1767607484,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，兴齐眼药报收于73.68元，较前一交易日上涨4.82%，最新总市值为181.57亿元。该股当日开盘72.48元，最高73.72元，最低70.8元，成交额达10.48亿元，换手率为7.6%。公司近日发布公告称，沈阳兴齐眼药股份有限公司收到国家药监局核准签发的硫酸阿托品滴眼液《药品补充申请批准通知书》，同意增加0.02%和0.04%两个规格。截至目前，国内外尚无同规格产品获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2600044798","title":"兴齐眼药最新公告：硫酸阿托品滴眼液药品补充申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2600044798","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600044798?lang=zh_cn&edition=full","pubTime":"2026-01-04 17:00","pubTimestamp":1767517253,"startTime":"0","endTime":"0","summary":"兴齐眼药公告称，公司收到国家药品监督管理局核准签发的硫酸阿托品滴眼液《药品补充申请批准通知书》。公司在已上市硫酸阿托品滴眼液基础上增加两个产品规格，分别为0.02%和0.04%。研究结果显示，0.02%和0.04%阿托品滴眼液与安慰剂相比，均能有效延缓儿童近视进展，且总体安全性良好。由于医药产品市场销售情况可能受多种因素影响，存在不确定性，敬请投资者谨慎决策，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010400002143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2600002064","title":"每周股票复盘：兴齐眼药（300573）生产许可证地址变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2600002064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600002064?lang=zh_cn&edition=full","pubTime":"2026-01-03 01:30","pubTimestamp":1767375031,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，兴齐眼药报收于70.29元，较上周的68.56元上涨2.52%。本周，兴齐眼药12月31日盘中最高价报71.28元。本周关注点公司公告汇总：药品生产许可证住所地址变更为辽宁省沈阳市浑南区新运河路25号。公司公告汇总关于公司药品生产许可证变更的公告沈阳兴齐眼药股份有限公司近日取得辽宁省药品监督管理局下发的《药品生产许可证》，主要变更为住所地址。生产地址和生产范围未发生变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773113314290,"stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":-0.0056},{"period":"3month","weight":-0.0579},{"period":"6month","weight":-0.019},{"period":"1year","weight":0.4075},{"period":"ytd","weight":-0.0182}],"compareEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":0.0076},{"period":"3month","weight":0.0479},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2147},{"period":"ytd","weight":0.0322}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54149人(较上一季度增加16.85%)","perCapita":"3500股","listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","registeredCapital":"24642万元","survey":"　　沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是眼科药物。公司先后荣获“辽宁省第九届省长质量奖银奖”、“辽宁五一劳动奖状”、“第十四届中国上市公司投资者关系天马奖”、第二十届“全国质量奖”、“国家级绿色工厂”、第十九届中国上市公司董事会金圆桌“优秀董事会”奖、中国上市公司协会“2024年度上市公司董办优秀实践案例”等奖项荣誉，并入选中国上市公司协会2024年上市公司可持续发展优秀实践案例，在眼科处方药物领域中处于优势地位。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}